Current and future CAR-T care processes are mapped, analyzed and enhanced under real-world constraints. Through expert interviews, observational studies, and KPI definition, partners will build detailed process diagrams and quantitative baselines to inform discrete-event simulation models. These models will be calibrated, used for “what-if” analyses to develop resource concepts (layout, staffing, logistics) and contribute to the performance evaluation in WP3. In parallel, qualitative co-creation workshops with clinicians ensure that user insights drive the design of optimized workflows, SOPs, and training materials.
To share EASYGEN’s findings with scientific, clinical, and public audiences the team develops a dynamic dissemination and communication strategy – featuring a unified brand identity, website, social media presence and toolkit for presentations and press releases. It conducts a literature review on CAR-T patient quality of life to inform targeted messaging and convenes roundtable workshops with patient advocacy groups to co-create educational resources and a white paper on lived-experience insights. Ongoing stakeholder networking ensures that healthcare providers and patients are actively engaged throughout the project’s lifespan.
Louise is a Project Manager at the EBMT with a Master of Science in Advancing Professional Healthcare Practice and an NHS Award in Executive Healthcare Leadership from the NHS Leadership Academy. She has over 10 years of clinical experience in the field of Haemato-Oncology, having served in roles such as Apheresis Specialist Nurse and Nurse Director. Louise is passionate about patient and family engagement, as well as enhancing the quality and governance of care. Her additional roles include serving as a JACIE inspector, Specialist Advisor for the Care Quality Commission (UK), and Associate Director of Private Care at The Royal Marsden in London.
Vaclovas is the EU Grants Coordinator at the EBMT. He holds a Master of Science degree in Biophotonics and has over a decade of experience in public funding for biomedical applications, pre-clinical development, and healthcare projects. At the EBMT, he is responsible for coordinating general, administrative, and financial activities in close collaboration with both internal teams and external stakeholders.
Tuula is the Director for Quality of Care and Advocacy at the EBMT. She holds a Master of Science in Public Services Policy and Management as well as a Master of Business Administration. Originally from Finland, she is a qualified Registered Nurse with over 20 years of clinical experience in the UK’s National Health Service. Her roles have included Clinical Nurse Specialist in Bone Marrow Transplantation and Apheresis, Quality Manager, and Service Manager. Tuula has been a JACIE inspector since 2008, served on the JACIE Accreditation Committeefrom 2016 to 2022, and chaired the JACIE Inspector Committee from 2020 to 2022. She has also contributed to the development of the 6th, 7th, and 8th editions of the FACT-JACIE Standards as a member of the corresponding review committees.
Anna Sureda is a clinical haematologist internationally recognized for her expertise in haematopoietic stem cell transplantation and cellular therapies. She is Head of the Haematology Department at the Institut Català d’Oncologia (ICO) in L’Hospitalet, Barcelona, Spain, and Associate Professor of Haematology at the University of Barcelona. Her clinical and research interests focus on lymphoid malignancies, particularly Hodgkin and non-Hodgkin lymphomas, using innovative transplant strategies and immunotherapeutic approaches, including CAR-T cell therapy. She has contributed significantly to advances in supportive care and the management of transplant-related complications. She is currently President of EBMT until 2026, having previously served as EBMT Secretary (2010–2016) and Chair of the Lymphoma Working Party (2004–2010).